On February 20, 2026, in REGENXBIO Inc. et al. v. Sarepta Therapeutics Inc., et al., No. 2024-1408, the Federal Circuit reversed a district court decision which held that claims covering a cultured ...
RJMPDRN REC is a vegan-certified recombinant PDRN produced through a patented biological synthesis platform using engineered ...
The first peer-reviewed journal in the field of human gene therapy, providing all-inclusive coverage of the research, methods, and clinical developments that are driving today's explosion of gene ...
The host cell system is a critical determinant of recombinant protein quality and yield, with direct influence on protein folding and post-translational modification factors that shape the ...
The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...
Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid ...
The DNA synthesis market offers significant growth opportunities driven by tailored therapies, DNA-based research, and diagnostics. Key market prospects include advancements in enzymatic synthesis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results